• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a new class of alkylsulfo- namidophenylalkylamines which are potent antiarrhythmic agents having good oral bioavailability properties.
    公开号:SU1424730A3
    申请号:SU853961255
    申请日:1985-10-14
    公开日:1988-09-15
    发明作者:Барнет Моллоу Брайан；Ирвин Стейнберг Митчелл
    申请人:Эли Лилли Энд Компани (Фирма)；
    IPC主号:
    专利说明:

     cm
    The invention relates to a class of new sulfonamide derivatives, in particular to a method for producing alkylsulfonamidophenylalknamines, having antiarrhythmic properties.
    The aim of the invention is to develop a method for producing new compounds with antiarrhythmic activity.
    Compounds which are semi-compound according to the proposed method have the following formula 1:
    / -L /
    RS02HN (CH2) n-C-N:
     R,
    where R is methyl
    R, -R, is hydrogen;
    R. - C, -C4-alkyl;
      C, -Ca-alkyl;
    n 2-4.
    The conversion of the aminophenyl intermediate to the corresponding 1ionium alkylsulfonamide substituted phenylalkylamine is carried out in accordance with known procedures. Preferably, the aminophenyl derivative is reacted with an alkylsulfonyl halide in the presence of an organic solvent and a suitable base; nor an acid acceptor. Typical organic solvents include chloroform, methylene chloride, DMF, benzool, toluene and other similar aprotic solvents. Suitable bases include triethylamine and inorganic bases such as sodium bicarbonate or potassium carbonate. When using pyridine as a solvent, which is preferred, it is not necessary to add an acid acceptor. Usually, the reaction practically ends after 1-72 hours when it is carried out in the temperature range from 0 to 150 C.
    The resulting product can be isolated using standard techniques. Normal volatile products are distilled off under reduced pressure, and the residue is stirred in water. The resulting paste is alkalinized with a base, for example ammonium hydroxide, to a pH in the range of 8-10. The product can be easily removed by extraction of the aqueous alkaline solution with a suitable water-immiscible

    fO
    five
    0
    5 5 0 5
    0
    a solvent, such as ethnyl acetate or chloroform, and evaporation of the solvent from the extract. The product introduced may be further purified, for example, by high performance liquid chromatography or crystallization according to standard procedures.
    Pharmaceutically acceptable acid addition salts are usually prepared by reacting a secondary or tertiary amine with an equimolar or excess amount of acid. The reactants are usually combined in a conventional solvent, such as diethyl ether or benzene, and the salt usually precipitates from solution over a period of 1 hour to 10 days and can be isolated by filtration.
    The invention is illustrated by the following examples.
    Example 1. H - {; 4- 4- (Ethylheptylamino) butnl phenyl methanesulfonamide ethanedithioate.
    A. N-Ethyl-K-heptl-4-nitrobenzene-butanamide.
    A 500 ml round bottom flask equipped with a feed funnel and a calcium sulfate drying tube was charged with 8.0 g (0.03 mol) of 4- (4-nitrophenyl) butyric acid in 180 vffl of carbon tetrachloride. While stirring, 16.5 ml (0.19 mol) of oxalyl chloride was added dropwise to this solution. The feed funnel was removed and a condenser was attached to the flask. The reaction mixture is heated under reflux for 3 hours, cooled and the excess oxalyl chloride is evaporated under reduced pressure. Approximately 100 ml of dry ethyl ether is added to the solution, which is then cooled on ice. To the cooled solution was added 16.3 g (0.115 mol) of ethylheptanine dissolved in about 60 ml of diethyl ether. The resulting reaction mixture was stirred overnight at room temperature and diluted with a mixture of water and diethyl ether. The aqueous phase is separated and extracted three times with diethyl ether. The organic extracts are combined, washed with water, hydrochloric acid, water (twice), with a 10% aqueous solution of sodium carbonate and with a saturated solution of sodium chloride. The organic phase is separated, dried over anhydrous.
    sulphate of sodium and extrude to dryness under reduced pressure. 12.8 A7 g of N-ethyl-N-heptyl-4-nitrophenyl-benzene-butanamide are obtained in the form of an oil.
    B. L-Ethyl-Y-heptyl-4-nitrobenzene-butlamine oxalate.
    A round-bottom flask with a capacity of 500 ml, equipped with a drying tube with glass wool, a thermometer, and a charging funnel, is charged with 114 np (0.114 mol) of diborane in a THF (Aldrich Chemical). A solution of 12.847 g (0.038 mol) of N-ethyl-M-heptyl-4-nitrobenzene-butane amide in 50 kp THF was added to this solution, keeping the temperature of the reaction mixture below 30 ° C.
    with the help of an outdoor water bath. The reaction mixture is stirred overnight N at room temperature and cooled on ice. A sufficient amount of 2N is added to the cooled solution. hydrochloric acid to decompose excess diborane and concentrate the reaction mixture under elevated pressure. 25 The resulting precipitate was combined with 150 Il 2N. hydrochloric acid and refluxed for about 30 minutes. The resulting mixture is cooled and alkalinized 5 n. Hydro-sodium oxide. The aqueous solution is extracted three times with diethyl ether, the organic extracts are combined and washed twice with water, twice with 2N, sulfuric acid, four times (Rhoda, once with 5N sodium hydroxide and once with a saturated solution of sodium chloride. The organic phase is dried over anhydrous sodium sulfate and extrude to dryness under reduced pressure of 40. 2.33 g of material is obtained, which is discarded. The sulfuric acid extracts are alkalized with 5N hydroxide of sodium and extracted three times with diethyl ether. kuyu promshayut phase with saturated sodium chloride solution and dried over anhydrous sodium sulfate, and after evaporation under
    %: C, 61.44; 8.35;
    35
    Calculated 6.82.
    С „Н„ Ы О
    Found,%: C 61.67-, H 8.48; N 6.98.
    C.4-Amino-K-ethyl-N-heptylbenzene-butanamine.
    4.4 g of S-ethyl-S-heptyl-4-nitrobenzene-butylaminium oxalate prepared above is converted into the free base using ammonium hydroxide. The aqueous solution is extracted with diethyl ether, the organic phase is concentrated in vacuo and 3.666 g of free base is obtained, which is dissolved in 95 ml of ethanol and hydrogenated at room temperature for 30 minutes B in the presence of 1 g of 5% palladium on carbon. The absorption of 100Z of hydrogen is observed. The reaction mixture was filtered through Celite and the filtrate was added to dryness under reduced pressure to obtain 3.114 g of 4-amino-N-ethyl-N-heptyl-benzenebutanamine. Additional quantities of this material are obtained according to the above general procedure.
    D. To a 250 ml three-neck round-bottomed flask equipped with a thermometer, charging funnel, and dried with calcium sulfate tube, 4.292 g (0.015 mol) of 4-akino-N-heptylbenzenebutanamine and 50 ml are charged.
    reduced pressure 10,547 g of go-pyridine material. The reaction mixture was cooled, having two spots per thin layer to about 10 ° C and added by chromatography. This material was dissolved in 1.5 ml (0.019 mol) of methanesulphate in 60 ml of acetic anhydride of fonyl chloride. The mixture is stirred all over and 10 drops of acetic acid are added at room temperature and with outgrowth. The reaction mixture is boiled for 1.5 hours gg evaporated under reduced pressure. The residue is combined with water and the pH of the resulting suspension is adjusted to 5.5-9.5 with concentrated hydrochloric acid at reflux, cooled and slowly poured into 500 ml of water-ice. The mixture was evaporated in vacuo and the residue was dissolved in water, ammonium basic alkali oxide. Alkalized mixture
    N 0 5 O 0 5
    chive 5 n. hydroxy sodium. The mixture is extracted three times with ethylether and the resulting organic extracts are combined, rIpock them with water and with an ethyl acetate solution, dried and concentrated, to obtain 10.334 g of K-ethyl-N-heptyl-4-nitrobei-zol-butanamine as an oil. This ma
    The terial is dissolved in ethyl acetate and
    combined with 2.92 g of oxalic acid dissolved in ethyl acetate. The solid precipitate is filtered off and recrystallized with ml of ethyl acetate, 8.963 g of N-ethyl-N-heptyl-4-nitrobenzene-butylamine oxalate are obtained. M.p. 115-117 s.
    %: C, 61.44; 8.35;
    five
    Calculated 6.82.
    С „Н„ Ы О
    Found,%: C 61.67-, H 8.48; N 6.98.
    C.4-Amino-K-ethyl-N-heptylbenzene-butanamine.
    4.4 g of S-ethyl-S-heptyl-4-nitrobenzene-butylaminium oxalate prepared above is converted into the free base using ammonium hydroxide. The aqueous solution is extracted with diethyl ether, the organic phase is concentrated in vacuo and 3.666 g of free base is obtained, which is dissolved in 95 ml of ethanol and hydrogenated at room temperature for 30 minutes B in the presence of 1 g of 5% palladium on carbon. The absorption of 100Z of hydrogen is observed. The reaction mixture was filtered through Celite and the filtrate was added to dryness under reduced pressure to obtain 3.114 g of 4-amino-N-ethyl-N-heptyl-benzenebutanamine. Additional quantities of this material are obtained according to the above general procedure.
    D. To a 250 ml three-neck round-bottomed flask equipped with a thermometer, charging funnel, and dried with calcium sulfate tube, 4.292 g (0.015 mol) of 4-akino-N-heptylbenzenebutanamine and 50 ml are charged.
    ammonium oxide. Alkalized mixture
    extract four times with chloroform and combine the organic extracts, wash with a saturated solution of sodium chloride and evaporate to dryness under noHiraeHHOM pressure, to obtain 5.916 g of material containing (ethylheptylamino) butylphenylJ-methanesulfonamide as a mill. Thin layer chromatography of the material indicates the absence of starting material.
    Sterling 5.916 g of the obtained material using high performance liquid chromatography. The gradient solvent is methylene chloride, up to 2.5% methanol (methylene chloride), 1% ammonium hydroxide. Fractions 26-32 were combined and the solvent was evaporated, to give 4.069 g of material. This material is dissolved in ethyl acetate and 1 g (0.012 mol) of oxalic acid dissolved in ethyl acetate is added thereto. A solid precipitate was obtained from the solid and recrystallized from ethyl acetate to obtain 3.8 D5 g of product, mp. 118-122 s. This material is recrystallized from ethyl acetate-methanol to give 3.677 g (ethylheptylamino) butyl phenyl-methanesulfonamide ethanedithioate, m.p. 120-122 ° C.
    Calculated,%: C 57.62; H 8.35; N 6.11; S 6.99.
    s.Nzv n.z.
    Found,%: C 57.71, - H 8.22; N 5.92; S 6.92.
    PRI mme R 2. K - ((ethylheptylamino) pentyl phenylJ-methanesulfon-amide-2-hydroxy-1,2,3-propane tetracarboxylate.
    A. 4-Nitrostyrol.
    A 500 ml three-neck round bottom flask was equipped with a thermometer and a device for steam stripping. A flask was charged with 12.5 g (0.054 MOhb) of A-nitropomethyl bromide, 75 ml (0.565 mol) of triethanolamine and 50 ml of water. The reaction mixture is heated under reflux and allowed to slowly distill off the vapor. Approximately 100 mg of hydroquinone is added to the collected distillate to prevent polymerization. The distillate was extracted three times with diethyl ether and the combined organic phases were washed with water, 1N hydrochloric acid, water, and a saturated solution of sodium chloride. The organic phase is dried over anhydrous sodium sulphate and above.
    50
    Dry with reduced pressure; 7.193 g of 4-nitrostyrene is obtained in the form of an oil, which solidifies upon cooling.
    B. N-Acethyl-4-nitrobenzoic acid, ethyl ester.
    To 65 ml of absolute ethanol in a nitrogen atmosphere add 700 mg of metallic sodium with stirring.
    to a 500 ml round-bottomed round-bottom flask equipped with a thermometer, a condenser, and a calcium sulfate desiccant tube. The mixture is heated to about 70 ° C to completely dissolve metallic sodium, and then cooled to room temperature. 19.5 g (0.091 mol) of ethyl acetoacetate and 14.1 (0.095 mol) of 4-nitrostyrene are charged to the mixture. The reaction mixture is boiled under reflux for about 6 hours and stirred overnight at room temperature. The mixture is drunk in 1 liter of water containing 4 MP of concentrated hydrochloric acid. The aqueous solution is extracted three times with diethyl ether, the organic extracts are combined, washed twice with water and once with a saturated solution of sodium chloride. The organic phase is dried over anhydrous sodium sulphate and evaporated to dryness under reduced pressure, 26.101 g of product are obtained in the form of an oil. Butter
    5 is dissolved in 100 ml of diethyl ether and cooled at about 0 ° C for 60 hours. A small amount of solid product is filtered off and the filtrate is concentrated in vacuo,
    0, 22.3 g of N-acetyl-4-nitrobenzenesulfonic acid are obtained in the form of ethyl ester (oil) in pure form.
    five
    0
    C. 5- (4-Nitrofe "il) -2-pentanone.
    A mixture of 22.3 g (0.080 mol) of K-acetyl-4-nitrobenzoylbutanoic acid ester and 500 mp of THF is charged in 250 ml of 6N hydrochloric acid and boiled overnight at reflux. The reaction mixture is cooled and evaporated to dryness under reduced pressure. The residue is diluted with water and extracted three times with diethyl ether. The organic extracts are separated, washed twice with 1 g of sodium hydroxide, three times with water and once with an effective sodium chloride solution. Organic.
    the solution is dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue is distilled to remove -chlorobutanol. The residue from this distillation was again distilled to a 6 - jacketed Vigreaux jacketed column and the 2nd fraction was 5- (A-nitrophenyl) -2-pentanone (6.681 g).
    D. N-Ethyl-N-methyl-4-nitrobenzapan-butanamine,
    A 300 ml round bottom flask equipped with a calcium sulfate drying tube was charged with 6.681 g.
    ten
    organic extracts, washed with water, 2 n. hydrochloric acid, twice with water and finally with a saturated solution of sodium chloride. The organic phase is dried over anhydrous sodium sulphate and evaporated to dryness under reduced pressure, to give 7.723 g of N-ethnl-N-1-methyl-A- (4-nitrophenyl) butyl-heptanamide as an oil,
    F. N-EtIm-N-Heptyl-L-Met tp- -pitrobenzenebutanamine.
    A three-neck round-bottom flask with a capacity of 500 MP is supplied with a condenser.
    (0.0322 mol) 5- (4-nitrophenyl) -2-foam-15 and a drying tube with glass wool.
    organic extracts, washed with water, 2 n. hydrochloric acid, twice with water and finally with a saturated solution of sodium chloride. The organic phase is dried over anhydrous sodium sulphate and evaporated to dryness under reduced pressure, to give 7.723 g of N-ethnl-N-1-methyl-A- (4-nitrophenyl) butyl-heptanamide as an oil,
    F. N-EtIm-N-Heptyl-L-Met tp- -pitrobenzenebutanamine.
    A three-neck round-bottom flask with a capacity of 500 MP is supplied with a condenser.
    100 ml of methanol. 13.2 g (0.161 mol) of ethylamine hydrochloride and 2.03 g (0.0322 mol) of sodium cyanoborohydride are loaded into this mixture. The resulting suspension is stirred at room temperature for about 72 hours and acidified with concentrated hydrochloric acid. The volatiles are distilled off under reduced pressure and 300 ml of water are added to the residue. The mixture was extracted twice with diethyl ether and the organic phase was washed with water and saturated sodium chloride solution. The organic phase is dried over anhydrous sodium sulphate and rotary dry. This material is discarded. The aqueous phase is alkalinized 5 n. sodium hydroxide and extracted three times with diethyl ether. Combine the organic extracts, wash with saturated sodium chloride solution, and dry over anhydrous sodium sulfate. After evaporation of the solvent, 6.838 g of H-ethyl-K-methyl-4-nitrobenzenebutanamine are obtained.
    E. N-Ethyl-H-L methyl-4- (4-nitrophenyl) butyl-heptanamide.
    In a 500 ml three-neck round bottom flask equipped with a thermometer
    rum and feed hopper, loading 0.74 g of 57th palladium per
    7.65 g sodium carbonate and 70 ml water. To this mixture was added 6.8 g (O, 029 mol) of N-ethyl-H-mets-1-4-nitrobenzene-butanamine and 70 ml of acetone. The resulting mixture is cooled to a temperature slightly below 25 ° C and 4.5 ml (0.029 mol) of heptanoyl chloride and 70 MP of acetone are added, maintaining the temperature of the mixture at 20-25 0. The suspension is stirred overnight at room temperature and evaporated to dryness under reduced pressure. The residue is taken up in a paste with water and extracted three times with diethyl ether. Unite
    50
    55
    coal Absorption is always 87% of theoretical hydrogen. The mixture is filtered through a filter and the filtrate is evaporated to dryness under a low pressure. 6.312 N-ethyl-M-heptyl-b-methy-1-4-aminobe zolbutanamine is obtained in the form of an oil.
    N. A three-neck, round-bottom, 250-np capacity, equipped with a thermo-rum, feed funnel, and a calcium sulfate tube, is charged with 6.3 g (0.021 mol) of K-ethyl-1 tnl-L-methyl-4-akinobenzenebutane and 90 MP dry pyridine. Received
    0 5 0 Q
    five
    A flask was charged with 60 Kl of 1 M diborane in TG and 7.7 g (0.022 mol) of K-ethyl-N-l-methyl-4- (4-nitropheyl) butyl-heptanamide in 50 ml of T1 F dropwise. the reaction mixture is refluxed overnight and cooled. A solution of 25 ml of 2N is added dropwise. hydrochloric acid to decompose any excess diborane. The mixture was reduced under reduced pressure and an additional 150 MP 2 n was added. hydrochloric acid. This mixture is refluxed for 1 hour, cooled and alkalinized with 5N. sodium hydroxide. The mixture is extracted three times with dithyl ether, the organic phase is washed with water and with a saturated solution of chloride. The organic phase is dried over sodium sulfate and evaporated to dryness to give 7.389 g of H-ethyl-L-heptyl-L-methyl-A-nitrobenzenebutanamine as an oil.
    G, M-Et1sh-L-heptyl-b-meth11-4-aminobenzenebutanamine.
    A mixture of 7.389 g (0.022 mol) of N-ethyl-β-heptyl-b-methyl-4-nitrobenzene-butane-amine in 92 ml of ethanol at room temperature overnight at 0
    five
    coal Absorption of just 87% of theoretical hydrogen is observed. The reaction mixture was filtered through Celite, and the filtrate was evaporated to dryness under reduced pressure, to give 6.312 g of H-ethyl-M-heptyl-b-methyl-4-aminobenzol-butanamine as an oil.
    H. A three-neck, 250 bp round-bottomed flask equipped with a thermometer, a charging funnel, and a calcium sulfate drying tube was charged with 6.3 g (0.021 mol) of K-ethyl-1 1 11-tnl-b-methyl-4-akinobenzenebutanamia and 90 MP dry pyridine. Received
    9-
    the mixture is cooled to IS C using an external ice bath and 2.2 MP (P, P 26 mol) of methanesulfonyl chloride are added, maintaining the temperature at about 15 ° C, external cooling is removed and the reaction mixture is stirred at night temperature . The volatiles are distilled off under reduced pressure and water is added to the residue. The pH of the mixture is adjusted to 5.7-9 with concentrated ammonium hydroxide. The aqueous phase is extracted three times with chloroform and the organic extracts are combined, washing them with a saturated aqueous solution of sodium chloride. The organic phase is dried over sodium sulfate and concentrated to 9, g of black oil.
    The resulting material is purified by high performance liquid chromatography. Fractions 31-35, containing 3.289 g of material, are combined with 1.98 g of citric acid in ttilat. The precipitates are filtered off and recrystallized from ethnol-acetone (95: 5 by volume) to give 4.516 g of (ethylheptylamino) phenyl phenyl methanesulfonamide 2-hydroxy -1,2,2-propane tricarboxylate, m.p. 73-76 C.
    Calculated,%: With 56,43; H 8.07; N 4.87; 5.58.
    .Cj HjjNjO, S
    Found,%: C 56.70; H 7.86; N 4.76; S 5.34.
    PRI me R 3. N - ((Butylhep tilamino) butnp phenyl} methanesulfonam ethanedioate.
    A. M-Butyl-M-heptyl-4-aminobeneolbutanamine.
    12.01 g (0.027 mol) of N-butyl-M-hep are converted into the free base.


    Tyl-4-nitrobenzenebut laminium oxalone

    that, having prepared a paste from this product in diethyl ether and ammonium hydroxide. The organic phase is separated and combined under reduced pressure, to give 9.519 g (0.027 mol) of the free base. This material is combined with 139 ml of methanol and hydrogenated at room temperature overnight in the presence of 1 g of 5% palladium.
    N
    Cj о Found:% C 59.47; H 8.48; 5.74; S 6.58.
    50
    PRI me R 4. (butylheptylamino) pentyl phenyl | methanesulfonamide.
    A. 4-Amino-Y-butyl-K-heptyl-b-methyl benzene butanamine.
    A solution of 16.2 g (0.045 mol) N-bu
    on coal. See the absorption of 88% of water-K-heptyl-b-methyl-4-nitrobenzene from the theoretical. The reaction mixture was filtered through celite and concentrated in vacuo. The residue is dissolved in ether and evaporated to dryness with ponibutane amine in 182 ml of ethanol and hydrogenated at room temperature overnight in the presence of 1.6 g of 5-palladium on charcoal. 74% absorption observed
    five
    D730
    Q
    0
    ten
    pressure, 8.584 g of L-butyl-L-heptyl-4-aminobenzolamine are obtained.
    B. A 250-neck, three-neck round-bottomed flask equipped with a thermometer, a charging funnel, and a Kalishch sulfate drying tube is charged with 8.5 g (0.027 mol) of N-butyl-M-heptyl-4-aminobenzenebutanamine and 90 ml of dry pyridine. . The reaction mixture is cooled to 10-15 ° C and 2.6 MP (0.034 mol) methanesulfonyl chloride are added thereto, keeping the temperature below about. The external ice bath is removed and the reaction mixture is stirred overnight at room temperature. Lunch is distilled off under reduced pressure and the pH of the reaction mixture is raised to about 9 by adding water and concentrated ammonium hydroxide. The aqueous solution is extracted four times with chloroform and the organic extracts are combined, washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate. The organic phase is concentrated, giving 12.246 g (butylheptylamino) butyphenyl jmethanesulfonamide as an oil.
    The resulting product is purified by high performance liquid chromatography. Fractions 26-32 are combined and the solvent is distilled off, 5 give 6.01 g of material. This material was dissolved in ethyl acetate and 1.43 g of oxalic acid dissolved in ethyl acetate was added. A solid precipitate was filtered off and recrystallized twice from ethyl acetate to obtain 2.934 g of M- {4-4- (butylheptylamino) butyl fencl methanesulfonamide ethanedioate, mp. 49-52 C.
    Calculated,%: C 59.23; H 8.70;
    0
    five
    0
     76 6.59.
    N
    Cj о Found:% C 59.47; H 8.48; 5.74; S 6.58.
    PRI me R 4. (butylheptylamino) pentyl phenyl | methanesulfonamide.
    A. 4-Amino-L-butyl-K-heptyl-b-methylbenzenebutanamine.
    A solution of 16.2 g (0.045 mol) of N-butyl-K-heptyl-b-methyl-4-nitrobenzenebutanamine in 182 ml of ethanol is hydrogenated at room temperature overnight in the presence of 1.6 g - 5% palladium on carbon. 74% absorption observed
    hydrogen from theoretical. The reaction mixture was filtered through Celite and the filtrate was evaporated under reduced pressure. The resulting material gives one spot at thin layer chromatography and represents 13.56 g of 4-amino-N-butyl-K-heptyl-β-L-methylbenzenebutanamine as an oil.
    B. A 250 ml three-necked round-bottomed flask equipped with a thermometer, a calcium sulfate desiccant tube and a funnel is charged with 13.56 g (0.041 mol) of 4-amino-L-butyl-M-heptyl-b-methylbenzene-15-tanamine. 175 ml of dry pyridine. The reaction mixture is cooled to approximately and 4.15 ml (0.052 mol) of methane sulfonated chloride is added there while maintaining the temperature of the reaction 20 mixture below about 15 ° C. The reaction mixture was stirred overnight at room temperature and the volatiles were distilled off under reduced pressure. The residue is taken up in a paste with water and adjusted to a pH of about 5.4 to 10 with concentrated ammonium hydroxide. The aqueous solution is extracted three times with chloroform and the organic extracts are combined, washed twice with aqueous SO and once with saturated aqueous sodium chloride solution. The organic phase is dried over anhydrous sodium sulphate and evaporated under reduced pressure.
    23.159 g of oil is obtained.
    The oil thus obtained is purified by high performance liquid chromatography. The fractions containing the main component are combined and the solvent is evaporated from them. The residue was distilled at a pressure of 0.01 mm, and the fraction boiling at about 225-240 ° C was collected; 4.169 g of N - ((butylheptylamino) -pentyl j phenyl) methanesulfonamide was obtained.
    Calculated,%: C, 67.27; H, 10.31; N 6.82; S 7.81.
    N
    c ,, h ,,
    Found,%: C 67.09, H 10.08, 6.93; S 7,61, Example
    N- {4 -C4- (Ethylheptylamino) butylZphenyl methanesulfonamide monohydrobromine.
    5.56 g (0.015 mol) of N (ethylheptylamino) butyl phenyl methanesulfonamide, prepared according to the general procedure described in Example 1, is dissolved in DIETSHLATE ester, prepared according to the general procedure described in example 1. Cool the solution in a dry ice bath.
    N N
    acetone and add to the bottom of the dichloride ether, saturated with gaseous broth. The volatiles were distilled off under reduced pressure, and 100 pp of ethyl acetate was added to the residue. The solution is thoroughly dissolved and approximately 6 g of crystals are collected. The solid product is recrystallized from isopropyl alcohol to obtain 2.5 g of - (ethylheptylamino) butyl phenyl methanesulfonylamide monohydrobromide, m.p. 98-100 C. Yield 37%.
    Found,%: C 53.66; H 8.57; 6.23; S 7.00; Вг 17,59.
    N N
    CzoHj BrNiO S
    Calculated,%: C, 53.44; H, 8.30; N 6.23; S 7.13; Вг 17,78.
    The following compounds were prepared by the above general procedures:
    EXAMPLE 6 K- {4-4- (Ztilheptypamino) butyl phenyl methanesulfonamide 4-methylbenzenesulfonate, m.p. 101uz with.
    Calculated,%: C 59.97; H 8.20, - N 5.18; S 11.86.
    ,, N, OsS
    Found,%: C 60.18, H 8.03; N 5.10; S 11.85.
    Example 7. N- {3- 4- (Ethylheptypamino) bynp3 phenyl} methanesulfonamide b.p. 215 ° C / 0.03 mm Hg
    N N
    Calculated,%: N 7.60; S 8,70. CzoHx N O S
    C 65.17; H 9.85;
    C, 64.92; H 9.58,
    Ы - ((Ethylhep: Found,%: N 7.73; S 8.96.
    Example
    tilamino) butyl phenyl} ethane ulfonamid, b.p. 205-220 ° C / 0.03 mmHg
    Calculated,%: C 65.92; H 10.01;
    N 7.32.
    C ,, H, i, N ,, 02S
    Found,%: C 65.86; H 9.82; N 7.03.
    Example 9. (dimethyl-amino) propyl Zfenip methanesulfonamide, m.p. 108-11 Gs.
    Calculated,%: C, 56.22; H 7.86; N 10.93.
    С, гН, 8МгОг5
    Found,%: C H 7.86; N 10.86.
    Example 10. (Butylheptylamino) pentyl | phenyl methanesul 1) onamide monohydrobromnd, m.p. 99-101 ° C.
    Calculated,%: C 56.20; H 8.82, N 5.70; Br 16.25; S 6.52.
    131A247
    C ,, H4,
    Nlydeno,%: C 56.39; H 8.64, - N 5.60; Br 16, A8; S 6.46.
    Example 11. N - ((Ethyl-heptylamino) butyl phenyl methanesulfon-amide, MO nogidrochloride, mp 99-101 C.
    Calculated,%: C 59.3i; -H 9.21; N 6.92; C1 8.75; S 7.92.

    Sgs
    , t
    N
    Found,%: C 59.55; H 9.07; 7.01; C1 8.95; S 8.02.
    The compounds of formula I are used for the treatment and prophylaxis of incoming arrhythmias.
    The specific dose of the compound I is determined in each particular case depending on the type of the administered compound, the route of administration, the condition of the patient, etc. Compounds may be administered in various ways, including oral rectal, transdermal, subcutaneous, intravenous, intramuscular or through the nose. The proposed compounds have good oral bioavailability without losing their potent anti-arrhythmic activity. The usual dosage for prophylactic treatment is about 0.2-20 mg / kg of active compound when administered orally. Preferably, the oral dose should be about 0.5-10 mg / kg, ideally about 1-5 mg / kg. For oral administration, the compounds of the formula I can be administered more than once a day, for example, after eight hours. For IV pills, the dose should be about 01.0-3000 µg / kg, preferably about 50-500 µg / kg,
    The compounds of the formula I have a high selective ability to prolong the duration of the potential effect on cardiac tissue, therefore they are especially indicated in the treatment of arrhythmias (they reduce the heart's susceptibility to incoming atrial and ventricular rhythms and fibrillation of the atria and ventricles during prolongation of electrical systole). Because the compounds increase the electrical stability of the heart, they are useful in combination with the use of external electrical devices designed to stop tachyarrhythm, such as ventricular tachycardia and ventricular fibrillation.
    The compounds obtained are effective in the conversion of scintillations.
    14
    0
    five
    0
    five
    0 0
    5 d g
    five
    ventricle and flutter, fibrillation or fast tachycardia in a normal sinusoidal rhythm. The compounds are useful in situations where there are inappropriately high ventricular velocities, especially in cases where a ventricular tachyarrhythmia is present. Preferably, the compounds are used to control incoming arrhythmias in humans and to prevent unexpected death as a result of febrile fibrillation.
    Extensive prolongation of the Qtc interval is usually indicative of non-uniform repolarization of cardiac cells within the heart. The advantages of the proposed compounds are that when administered intravenously, they have the ability to reduce the prolongation of the Qtc interval for a given increase in immunity compared to other known antiarrhythmic agents such as clofilium.
    A pharmaceutical formulation comprising the subject compounds furthermore contains a pharmaceutically acceptable carrier, diluent or excipient.
    Pharmaceutical formulations are prepared by known methods using known and easily available ingredients. In making the compositions, the active ingredient will usually have to be mixed with a carrier or diluent, or diluted with a carrier, or enclosed inside a carrier, which may be in the form of a capsule, pouch, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material that acts as a carrier, excipient, or medium for the active ingredient.
    The compositions can be in the form of tablets, pilchsh, powders, lotions, sachets, wafers, elixir, suspensions, emulsions, syrups, aerosols (as solid or in a liquid medium), ointments containing for example up to 10% by weight. active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
    Lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, phosphate can be used as carriers, excipients and diluents.
    calcium, alginates, tragacanth, gelatin, calysh silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl and propyloxybenzene, talc, magnesium stearate and mineral oil. Formulations may additionally contain lubricants, wetting agents, emulsifiers and suspending agents, preservatives, sweeteners and perfumes. Compositions can be formulated so as to provide a quick, long or delayed release of active ingredient after administration to a patient using known procedures.
    Each dose of the composition contains about 5-500 mg, usually about 25-300 mg of active ingredient (single dose - a certain amount of active material calculated to half the desired therapeutic effect).
    Examples of formulations are presented below.
    Example 12. Prepare hard gelatin capsules using the following ingredients, mg / capsule:
    H- {4- | 4- (Ethylheptyl-
    amino) butyl phenyl jMethenesulfonamide ethanedithioate 250
    Dried starch 200
    Magnesium stearate 10
    The ingredients are mixed and filled with hard gelatin capsules of 460 mg each.
    Example 13. Preparing tablets using the following ingredients, mg / tablet: (8ytilheptyl-amino) butyl phenylmethanesulfonamide ethanedithioate
    Microcrystalline
    cellulose
    Silicon dioxide, smoke
    Stearic acid
    The components are mixed and compressed into tablets, each weighing 665 mg.
    Example 14. Preparing an aerosol solution containing the following components, wt%:
    N - fA- 4- (Ethylheptylamino) pentyl phenyl, methanesulfonamn-2-hydroxy-1, 2,3-propantricarboxylate 0,25
    250
    400
    ten
    five
    five
    0
    five
    0
    Q
    five
    five
    0
    five
    Ethanol29, 75
    Propellant 2270.00
    (Chlorodifluorometay). The active component is mixed with ethanol, the mixture is added to a portion of propellant 22 cooled to -30 ° C and transferred to a casting device. The required amount is then fed to a stainless steel container and diluted with the remainder of the prollant. Then the container is equipped with a valve.
    Example 15. Preparing tablets containing, mg / tablet: (In Gilgeptylamino) pentyl phenyl methane sulfonamide 60
    Starch45
    Microcrystalline Cellulose35
    Polyvinylpyrrolidone (10% solution in water) 4 Sodium carboxymethyl starch 4.5 Magnesium stearate 0.5
    Talc1
    The active ingredient, starch and cellulose are passed through a No. 45 U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the obtained powder, then passed through a No. 14 mesh US sieve. The granules thus obtained are dried at 50-60 ° C and passed through a No. 18 mesh US sieve.
    Katharycarboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules, which, after mixing, are compressed on a tablet machine to obtain tablets weighing 150 mg each.
    PRI me R 16. Prepare capsules containing 1 mg / capsule. (Ethylheptylamino) butyl phenyl} methanesulfonamide80
    Starch59
    Microcrystalline cellulose .59
    Magnesium stearate 2
    The active ingredient, cellulose, starch, and magnesium stearate, mix Tacal, is passed through a No. 45 mesh U.S. sieve and filled into this mixture of hard gelatin capsules of 200 mg each. Such an oral composition is especially
    It is recommended for patients who receive treatment using electric defibrillated devices.
    Example 17. Candles are prepared, each of which contains, mg: N- {4- A- (ethylheptylamino) butyl phenyl ethanesulfonamide225
    Glycerides nadidnoy fat-
    Acid AcidTo 2000
    The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in pre-molten saturated fatty acid hydrides using minimal amount of heat to melt. The mixture is then poured into a candle mold with a nominal capacity of 2 g and allowed to cool.
    Example 18. The following ingredients are prepared as suspensions containing 5 ml:
    N- {4- 3- (Limethylam-11-no) propyl phenyl methane sulfonamide, mg 50
    Haptrai Carboxymethyl Cellulose, mg50 Syrup, Benzoic Acid Solution, kp 0.10 Purified Water, ml Up to 5 The drug is passed through a No. 45 mesh US sieve and mixed with the carboxymethylcellulose sodium and syrup to form a soft paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added with stirring. Water is then added to obtain a predetermined volume.
    Example 19. An intravenous solution is prepared containing:
    N- {3- 4- (Ethylheptyls
    but) SutilZ phenyl} methane
    sulfones u, mg100
    Saline,
    ml1000
    A solution of the above ingredients is administered intravenously at a rate of 1 MP per minute to persons suffering from ventricular fibrillation.
    The antiarrhythmic activity of the proposed compounds is determined using standard electrophysiological techniques to measure the residual potential, the amplitude of the actual potential, the duration, the rate of increase, and the period
    Q
    15
    20
    25
    30 Q
    five
    An effective immunity of normal Parkinew dog fibers superinduced in vitro in Ringer's solution at 35 ° C and moving at a constant frequency of 1 Hz.
    Below is the data obtained for a number of pretreated compounds assessed by this test, namely, the percentage increase in the duration of the potential effect at 93% complete repolarization at 10 M).
    Connection according to example 1 31 + 6
    3 26 + 4
    720 + 9
    819 + 4 Some of the compounds of formula I
    were tested on dogs anaesthetized with a gallotan to evaluate the effectiveness of the compounds to increase the period of effective ventricular immunity,
    The table shows the amount of compound required to increase the immunity period by 30 ms with its intravenous or intraduodenal administration. The compounds were tested against clofolium and C-ethyl-M-heptyl-4-nitroC5-sol-butanamine, ethanedithione salt.
    权利要求:
    Claims (2)
    [1]
    As can be seen from the table, compounds I obtained according to the proposed method show a higher antiarrhythmic activity as compared with the known and less toxic ones. Invention Formula
    The method of producing methylsulfonamidophenylalkylamines of the general formula
    Rt
    .БЗ
    I /
    RS02HN - (CH2) n-C-Nv
    R 2 R
    1 where R is methyl;
    R and RJ are hydrogen;
    RJ - C, -C4-alkyl; R - C, -Sv-alksht,
    P
    [2]
    2 ... And,
    or their pharmaceutically acceptable acid addition salts, characterized in that the amine of the general formula
    (CHzlpC- N V.
    .БЗ
    R /,
    19142473020
    where R, -R4 have the indicated meanings, where X is a halogen,
    reacted with methyl and, if necessary, carried out with a sulphonyl agent of the general formula, formation to form a pharmaceutically acceptable additive salt
    CHSO X,
    acid.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1424730A3|1988-09-15|Method of producing methylsulfonamidophenylalkyl amines and their pharmaceutically acceptable salts
    AU2003229734B2|2009-02-19|Hydroxy tetrahydro-naphthalenylurea derivatives
    JP2637737B2|1997-08-06|New drugs
    EP0048045A1|1982-03-24|Phenyl piperazine derivatives having antiagressive activity
    US5981595A|1999-11-09|Sulfonyl urea and carbamate ACAT inhibitors
    KR20040030668A|2004-04-09|Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds
    AU641676B2|1993-09-30|Antiarrhythmic tertiary amine-alkenyl-phenyl-alkanesulfonamides
    FI74703B|1987-11-30|PROCEDURE FOR FRAMSTATION OF THERAPEUTIC VERKSAMMA 3,1-BENZOZAZINE-2-ONER.
    PL91560B1|1977-03-31|
    IE45298B1|1982-07-28|Hypoliidaemic compositions
    US4596827A|1986-06-24|Alkylsulfonamidophenylalkylamine compounds used for treating arrhythmia
    EP0221958B1|1992-10-28|3-aminopropyloxyphenyl derivatives their preparation and pharmaceutical compositions containing them
    US5635511A|1997-06-03|Treatment of heart rhythm disorders by administration of 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds.
    CZ2001858A3|2001-06-13|Use of benzenesulfonyl| ureas for treating and prophylaxis of autonomous nervous system dysfunctions and use of the benzenesulfonyl| ureas in combination with beta-receptor blockers
    US2449638A|1948-09-21|Substituted glycinamides
    JP3905573B2|2007-04-18|Substituted benzenesulfonylureas and -thioureas, processes for their preparation and the use of pharmaceutical preparations based on these compounds and medicaments containing them
    JP4132115B2|2008-08-13|Substituted chromanylsulfonyl | ureas, their preparation, their use in pharmaceutical formulations and pharmaceutical formulations containing them
    EP0167245B1|1987-06-16|Anti-arrhythmic agents
    US4814330A|1989-03-21|3-phenyl-1-propanones, process of preparing thereof and method of treating arrhythmias
    HU9602331A2|1997-05-28|Alkenyl-benzoyl-guanidine derivatives, pharmaceutical compns. contg. the said compds., process for preparing them and the use of the compds.
    HU194213B|1988-01-28|Process for production of 3-alkoxi-2-n-pirrolidin-n-piridil-n-furil /or n-tienil/-methil-prophil amins
    US3917679A|1975-11-04|Quaternary ammonium salts of N-dialkylaminoalkyl-N-|anilines
    US4015002A|1977-03-29|1-Aryl-2-oxo-2,4,5,6,7,7a-hexahydro-indoles, salts, pharmaceutical compositions and methods of use
    JPH08245555A|1996-09-24|Substituted benzenesulfonyl-urea and -thiourea, method of preparing them, their use for production of medicinal preparations and medicines containing them
    US5334602A|1994-08-02|Aryloxalkylamine derivatives and uses thereof
    同族专利:
    公开号 | 公开日
    ES547840A0|1986-09-01|
    ES8609229A1|1986-09-01|
    PT81299A|1985-11-01|
    DK468185D0|1985-10-14|
    JPS6197256A|1986-05-15|
    PT81299B|1988-02-17|
    AT41922T|1989-04-15|
    GR852496B|1986-02-18|
    AU4855885A|1986-04-24|
    AU586644B2|1989-07-20|
    NZ213812A|1989-01-06|
    KR860003210A|1986-05-21|
    DK164450C|1992-11-16|
    DK164450B|1992-06-29|
    EP0178874A1|1986-04-23|
    HUT38610A|1986-06-30|
    KR880001008B1|1988-06-13|
    CN1004133B|1989-05-10|
    AR241528A1|1992-08-31|
    DK468185A|1986-04-16|
    EP0178874B1|1989-04-05|
    US4569801A|1986-02-11|
    IL76707D0|1986-02-28|
    HU195479B|1988-05-30|
    CN85107020A|1986-04-10|
    ZA857871B|1987-05-27|
    CA1291165C|1991-10-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR152F|1962-01-24|
    US3574741A|1969-04-14|1971-04-13|Mead Johnson & Co|Sulfonamidophenalkylamines|
    HU173192B|1973-08-13|1979-03-28|Fujisawa Pharmaceutical Co|Process for producing new phenylglycine derivatives|
    US4336269A|1979-12-10|1982-06-22|Eli Lilly And Company|Para-nitrophenylalkylamines|
    US4277501A|1977-12-19|1981-07-07|Eli Lilly And Company|Para-nitrophenylalkylamines and pharmaceutical compositions|
    US4289787A|1977-12-19|1981-09-15|Eli Lilly And Company|Quaternary ammonium antiarrhythmic drugs|
    IL57670A|1978-07-03|1982-11-30|Lilly Co Eli|Phenethanolamines,their preparation and pharmaceutical formulations comprising them|
    DE3566886D1|1984-05-04|1989-01-26|Upjohn Co|N-sulfonamides their preparation and therapeutic use|US5155268A|1984-05-04|1992-10-13|The Upjohn Company|Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides|
    GB8609630D0|1986-04-19|1986-05-21|Pfizer Ltd|Anti-arrhythmia agents|
    EG18188A|1986-05-01|1992-09-30|Pfizer Ltd|Process for preparation anti-arhythmia agents|
    GB8706662D0|1987-03-20|1987-04-23|Pfizer Ltd|Anti-arrhythmia agents|
    DE3732094A1|1987-09-24|1989-04-06|Basf Ag|BISPID DERIVATIVES AS CLASS III ANTIARRHYTHMICS|
    US4906634A|1988-03-08|1990-03-06|Schering A.G.|Novel N-[4-phenyl]methanesulfonamides and their use as cardiovascular agents|
    US5238959A|1988-04-08|1993-08-24|Eli Lilly And Company|3-phenyloxy-3-phenyl propanamines|
    ZA892517B|1988-04-08|1990-12-28|Lilly Co Eli|Propanamine derivatives|
    US5405997A|1989-07-25|1995-04-11|The Upjohn Company|Antiarrhythmic methanesulfonamides|
    CA2196064A1|1994-09-12|1996-03-21|Jackson B. Hester, Jr.|4-butylamine derivatives with antiarrhythmic activity|
    US5874475A|1995-12-21|1999-02-23|Pharmacia & Upjohn Company|Antiarrhythmic -enantiomers of methanesulfonamides|
    US5971983A|1997-05-09|1999-10-26|The Regents Of The University Of California|Tissue ablation device and method of use|
    US6652515B1|1997-07-08|2003-11-25|Atrionix, Inc.|Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall|
    US6607502B1|1998-11-25|2003-08-19|Atrionix, Inc.|Apparatus and method incorporating an ultrasound transducer onto a delivery member|
    US6164283A|1997-07-08|2000-12-26|The Regents Of The University Of California|Device and method for forming a circumferential conduction block in a pulmonary vein|
    US6514249B1|1997-07-08|2003-02-04|Atrionix, Inc.|Positioning system and method for orienting an ablation element within a pulmonary vein ostium|
    US6012457A|1997-07-08|2000-01-11|The Regents Of The University Of California|Device and method for forming a circumferential conduction block in a pulmonary vein|
    US6500174B1|1997-07-08|2002-12-31|Atrionix, Inc.|Circumferential ablation device assembly and methods of use and manufacture providing an ablative circumferential band along an expandable member|
    US6966908B2|1997-07-08|2005-11-22|Atrionix, Inc.|Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall|
    US6997925B2|1997-07-08|2006-02-14|Atrionx, Inc.|Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall|
    US6024740A|1997-07-08|2000-02-15|The Regents Of The University Of California|Circumferential ablation device assembly|
    US6245064B1|1997-07-08|2001-06-12|Atrionix, Inc.|Circumferential ablation device assembly|
    US6869431B2|1997-07-08|2005-03-22|Atrionix, Inc.|Medical device with sensor cooperating with expandable member|
    WO2000010557A1|1998-08-25|2000-03-02|Nippon Shinyaku Co.,Ltd.|Stabilized solid preparations|
    EP3369453B1|1999-05-11|2020-03-18|Atrionix, Inc.|Medical device positioning system including a balloon anchor wire|
    US6758830B1|1999-05-11|2004-07-06|Atrionix, Inc.|Catheter positioning system|
    US6599288B2|2000-05-16|2003-07-29|Atrionix, Inc.|Apparatus and method incorporating an ultrasound transducer onto a delivery member|
    AU6682401A|2000-06-13|2001-12-24|Atrionix Inc|Surgical ablation probe for forming a circumferential lesion|
    AU777681B2|2000-09-08|2004-10-28|Atrionix, Inc.|Medical device with sensor cooperating with expandable member|
    US6755822B2|2001-06-01|2004-06-29|Cryocor, Inc.|Device and method for the creation of a circumferential cryogenic lesion in a pulmonary vein|
    JP2005524496A|2002-05-08|2005-08-18|ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア|System and method for non-destructive cardiac conduction block formation|
    US6786202B2|2002-09-24|2004-09-07|Caterpillar Inc|Hydraulic pump circuit|
    US7317950B2|2002-11-16|2008-01-08|The Regents Of The University Of California|Cardiac stimulation system with delivery of conductive agent|
    US20040106896A1|2002-11-29|2004-06-03|The Regents Of The University Of California|System and method for forming a non-ablative cardiac conduction block|
    US6932804B2|2003-01-21|2005-08-23|The Regents Of The University Of California|System and method for forming a non-ablative cardiac conduction block|
    US7670335B2|2003-07-21|2010-03-02|Biosense Webster, Inc.|Ablation device with spiral array ultrasound transducer|
    US7247269B2|2003-07-21|2007-07-24|Biosense Webster, Inc.|Method for making a spiral array ultrasound transducer|
    EP1706052B1|2003-12-31|2011-05-04|Biosense Webster, Inc.|Circumferential ablation device assembly with dual expandable members|
    US20060270900A1|2005-05-26|2006-11-30|Chin Albert K|Apparatus and methods for performing ablation|
    US8932208B2|2005-05-26|2015-01-13|Maquet Cardiovascular Llc|Apparatus and methods for performing minimally-invasive surgical procedures|
    US20070185479A1|2006-02-06|2007-08-09|Liming Lau|Methods and devices for performing ablation and assessing efficacy thereof|
    US20070225697A1|2006-03-23|2007-09-27|Ketan Shroff|Apparatus and methods for cardiac ablation|
    US20080039879A1|2006-08-09|2008-02-14|Chin Albert K|Devices and methods for atrial appendage exclusion|
    US8728073B2|2006-10-10|2014-05-20|Biosense Webster, Inc.|Multi-region staged inflation balloon|
    US8512387B2|2007-09-07|2013-08-20|Robert S. Fishel|Esophageal cooling system for ablation procedures associated with cardiac arrhythmias|
    JP2010540160A|2007-10-05|2010-12-24|マッケカーディオバスキュラー，エルエルシー|Apparatus and method for minimally invasive surgical procedures|
    US20090209986A1|2008-02-15|2009-08-20|Stewart Michael C|Devices, Tools and Methods for Atrial Appendage Exclusion|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US06/660,816|US4569801A|1984-10-15|1984-10-15|Alkylsulfonamidophenylalkylamines|
    [返回顶部]